AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02412150 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ramsay Sedation Scale
Description: When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~1. Awake Patient anxious and agitated or restless or both!~2. Patient cooperative, oriented and tranquil!~3. Patient responds to commands only!~4. Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~5. A sluggish response to a light glabellar tap or loud auditory stimulus!~6. No response to a light glabellar tap or loud auditory stimulus
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extubation time and Recovery time
Description: The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured.
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Extubation time and Recovery time
Description: The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured.
Study NCT02412150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Description: The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
Study NCT02412150 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Visual analogue scale
Description: The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative bleeding
Description: The amount of postoperative bleeding which is collected in the barovac is measured.
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative bleeding
Description: The amount of postoperative bleeding which is collected in the barovac is measured.
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Description: Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative complications
Description: Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time to remove drainage and duration of hospital staying
Description: The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
Study NCT02412150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Time to remove drainage and duration of hospital staying
Description: The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
Study NCT02412150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
Study NCT02412150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
Study NCT02375100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
Study NCT02375100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
Study NCT02375100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
Study NCT02375100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilioinguinal Nerve Block
Description: Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
Study NCT02375100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine %0.5 (hyperbaric)
Study NCT02375100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine %0.5 (hyperbaric)
Study NCT02375100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine %0.25 (isobaric)
Study NCT02375100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25G Quincke needle
Study NCT02375100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25G Quincke needle
Study NCT02375100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echogenic Needle with 30° bevel
Study NCT02375100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
Study NCT02375100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
Study NCT02375100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
Study NCT02375100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
Study NCT02271529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX® Drug-Eluting Peripheral Stent
Description: Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
Study NCT00569933 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio recording
Description: Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
Study NCT01250054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
Study NCT01250054 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
Study NCT01227785 — intervention group
Intervention type: DEVICE
Intervention: INCEPTA ICD or CRT-D
Study NCT03637491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: IV treatment
Study NCT03637491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Oral treatment
Study NCT03637491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral treatment
Study NCT04051177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Communication with Openness, Passion, and Empowerment ICOPE
Description: The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions.
Study NCT04051177 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Curriculum
Description: The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)
Study NCT01276106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201, 25mg
Description: Capsule, 25mg BID
Study NCT01276106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201, 50mg
Description: Capsule, 50mg BID
Study NCT02344641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study NCT05150067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Blended Learning Programme
Description: A blended learning programme with face-to-face training and an online module on handover practice
Study NCT01276106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201, 75mg
Description: Capsule, 75mg BID
Study NCT01276106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study NCT02066649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Administering carvedilol to patients diagnosed with large varices on endoscopy
Study NCT02066649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variceal band ligation
Description: Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
Study NCT00656682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietitian Counseling Alone
Description: Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
Study NCT00656682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian Plus Community Group Lifestyle
Description: Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
Study NCT02026011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
Study NCT02026011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill, matched to the active study medication in capsule size and color
Study NCT02805543 — intervention group
Intervention type: DEVICE
Intervention: Color doppler imaging
Study NCT03224039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Intranasal for one dose (experimental)
Study NCT03224039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
Study NCT03224039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
Study NCT03224039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenous push for one dose (active comparator)
Study NCT01709526 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Improvement after psychiatric inpatient treatment
Description: Cognition, psychosocial functioning
Study NCT01730872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
Description: One drop in each eye, four times/day for 4 days.
Study NCT01730872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tears Naturale II Ophthalmic Solution
Description: one drop in each eye, four times/ day (QID) for 4 days
Study NCT03343561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Advice
Description: Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
Study NCT05150067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control group
Description: The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
Study NCT00757133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional laparotomy closure
Description: Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
Study NCT00757133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy closure with mesh augmentation
Description: Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias
Study NCT05638308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FAZA PET/MRI scan
Description: FAZA PET/MRI scan before the standard of care biopsy for case group
Study NCT03817476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T1)
Description: Intended commercial formulation tablet from batch 1 (iCF1)
Study NCT03817476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment T2)
Description: Intended commercial formulation tablet from batch 2 (iCF2)
Study NCT03817476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (Treatment R)
Description: Trial formulation 2 tablet (TF2)
Study NCT00945789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin
Description: Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
Study NCT00945789 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: EEG and Brain MRI
Description: EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
Study NCT00945789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG and Brain MRI
Description: EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
Study NCT00945789 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Nitric oxide measurement in the blood
Description: Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
Study NCT00682149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)
Description: 1 tablet/day for 3 months
Study NCT00682149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)
Description: 1 tablet/day for 3 months
Study NCT04197284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback, Myomed 632
Description: Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses.
Study NCT04197284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: device for electrical stimulation, BTL 4000 Smart
Description: Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.
Study NCT04197284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesitherapy
Description: isometric exercise of the quadriceps muscle
Study NCT00334958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rufinamide
Description: For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
Study NCT00025363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00945789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nitric oxide measurement in the blood
Description: Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
Study NCT00767338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemination
Description: Intrauterine insemination
Study NCT00945789 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nitric oxide measurement in the blood
Description: Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
Study NCT04169698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml [Prolia]
Description: full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
Study NCT04169698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate 70Mg Tab
Description: Bisphosphonates
Study NCT01824290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
Study NCT01824290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
Study NCT01824290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ERA as specific PAH treatment
Description: All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
Study NCT01824290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERA as specific PAH treatment
Description: All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
Study NCT02343770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample for identifying biomarkers
Study NCT02343770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample for identifying biomarkers
Study NCT00175929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Study NCT00175929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Study NCT00175929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Study NCT00362895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension
Description: One drop in the study eye, single dose
Study NCT00362895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)
Description: One drop in the study eye, single dose